- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Di | Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows | 3 | Seeking Alpha | ||
| KINIKSA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | 80 | GlobeNewswire (Europe) | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| 27.10. | What to Expect from Kiniksa Pharmaceuticals' Earnings | 10 | Benzinga.com | ||
| 27.10. | Kiniksa Pharmaceuticals International, plc Q3 2025 Earnings Preview | 2 | Seeking Alpha | ||
| 22.10. | Kiniksa stock price target maintained at $60 by TD Cowen on strong Arcalyst sales | 1 | Investing.com | ||
| 22.10. | TD Cowen bestätigt Kursziel für Kiniksa bei 60 Dollar - Starke Arcalyst-Umsätze als Treiber | 2 | Investing.com Deutsch | ||
| 17.10. | 5 Analysts Have This To Say About Kiniksa Pharmaceuticals | 1 | Benzinga.com | ||
| 17.10. | Kiniksa Pharmaceuticals Says FDA Grants Orphan Drug Designation For KPL-387 To Treat Pericarditis | - | RTTNews | ||
| 17.10. | FDA erteilt Kiniksa Orphan-Drug-Status für Medikament gegen Perikarditis | 11 | Investing.com Deutsch | ||
| 17.10. | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis | 193 | GlobeNewswire (Europe) | LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases... ► Artikel lesen | |
| 14.10. | Earnings Call: Kiniksa Pharmaceuticals meldet starkes Wachstum im zweiten Quartal 2025 und hebt Prognose an | 2 | Investing.com Deutsch | ||
| 29.09. | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | 1 | Benzinga.com | ||
| 29.09. | Kiniksa stock initiated with Buy rating at TD Cowen on Arcalyst growth potential | 1 | Investing.com | ||
| 29.09. | TD Cowen startet Kiniksa-Aktie mit Kaufempfehlung - Wachstumspotenzial von Arcalyst im Fokus | 1 | Investing.com Deutsch | ||
| 03.09. | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA? | 1 | Zacks | ||
| 02.08. | Gold Fields, Kiniksa Join Best Stock Lists As They Defy Slump And Shares Pop: See New Names On IBD 50, IPO Leaders And More | 8 | Investor's Business Daily | ||
| 29.07. | Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report | 3 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,35 | +0,17 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| BB BIOTECH | 44,550 | +0,56 % | BB Biotech - Turning milestones into momentum | BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0%... ► Artikel lesen | |
| CUREVAC | 4,572 | -1,08 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| AMGEN | 259,70 | +0,78 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,338 | +0,60 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 134,75 | +0,60 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 568,00 | +0,39 % | Aktien New York: Rekordrally setzt sich fort - Optimismus bei KI-Aktien | NEW YORK (dpa-AFX) - Die Rekordrally an den US-Börsen hat sich am Dienstag fortgesetzt. "Die KI-Party in New York geht weiter", kommentierte Christine Romar, Head of Europe beim Broker CMC Markets.... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | -2,67 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,520 | +1,53 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| INTELLIA THERAPEUTICS | 11,110 | +0,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 78,50 | +0,64 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| BIOCRYST PHARMACEUTICALS | 6,504 | +2,30 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,140 | +1,54 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| BIOMARIN PHARMACEUTICAL | 44,770 | -3,58 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen |
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 36,980 Euro und damit -0,83 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KINIKSA PHARMACEUTICALS INTERNATIONAL PLC finden Sie auf Wallstreet Online.